Search

Your search keyword '"Oene, Joop van"' showing total 3 results
Start Over Author "Oene, Joop van"
3 results on '"Oene, Joop van"'

1. Long-term risk of hepatocellular carcinoma mortality in 23220 hospitalized patients treated with micafungin or other parenteral antifungals

Author

Schneeweiss, Sebastian, primary, Carver, Peggy L, additional, Datta, Kausik, additional, Galar, Alicia, additional, Johnson, Melissa D, additional, Letourneau, Alyssa R, additional, Marty, Francisco M, additional, Nagel, Jerod, additional, Najdzinowicz, Maryann, additional, Saul, Melissa, additional, Schuster, Mindy, additional, Shoham, Shmuel, additional, Silveira, Fernanda P, additional, Varughese, Christy, additional, Wilck, Marissa, additional, Weatherby, Lisa, additional, Oene, Joop van, additional, and Walker, Alexander M, additional

Published
2019
Full Text
View/download PDF

2. Long-term risk of hepatocellular carcinoma mortality in 23220 hospitalized patients treated with micafungin or other parenteral antifungals.

Author

Schneeweiss, Sebastian, Carver, Peggy L, Datta, Kausik, Galar, Alicia, Johnson, Melissa D, Letourneau, Alyssa R, Marty, Francisco M, Nagel, Jerod, Najdzinowicz, Maryann, Saul, Melissa, Schuster, Mindy, Shoham, Shmuel, Silveira, Fernanda P, Varughese, Christy, Wilck, Marissa, Weatherby, Lisa, Oene, Joop van, and Walker, Alexander M

Subjects
HOSPITAL patients, HEPATOCELLULAR carcinoma, ELECTRONIC health records, CARCINOGENICITY, MORTALITY, ANTIFUNGAL agents, RESEARCH, LIVER tumors, TIME, RESEARCH methodology, RETROSPECTIVE studies, MEDICAL cooperation, EVALUATION research, PARENTERAL infusions, COMPARATIVE studies, HOSPITAL care, FUNGEMIA, PROBABILITY theory
Abstract

Background: Liver tumours observed in rats exposed to micafungin led to a black box warning upon approval in Europe in 2008. Micafungin's risk for liver carcinogenicity in humans has not been investigated. We sought to describe the risk of fatal hepatocellular carcinoma (HCC) among persons who received micafungin and other parenteral antifungals (PAFs) with up to 12 years of follow-up.Methods: We assembled a US multicentre cohort of hospitalized patients who received micafungin or other PAFs between 2005 and 2012. We used propensity score (PS) matching on patient characteristics from electronic medical records to compare rates of HCC mortality identified through the National Death Index though to the end of December 2016. We computed HRs and 95% CIs.Results: A total of 40110 patients who received a PAF were identified; 6903 micafungin recipients (87% of those identified) were successfully matched to 16317 comparator PAF users. Ten incident HCC deaths, one in the micafungin-exposed group and nine among comparator PAF users, occurred in 71285 person-years of follow-up. The HCC mortality rate was 0.05 per 1000 person-years in micafungin patients and 0.17 per 1000 person-years in comparator PAF patients. The PS-matched HR for micafungin versus comparator PAF was 0.29 (95% CI 0.04-2.24).Conclusions: Both micafungin and comparator PAFs were associated with HCC mortality rates of <0.2 per 1000 person-years. Given the very low event rates, any potential risk for HCC should not play a role in clinical decisions regarding treatment with micafungin or other PAFs investigated in this study. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

3. Perimenstrual migraines and their response to preventive therapy with topiramate

Author

Allais, Gianni, Sanchez Del Rio, Margarita, Diener, Hans Christoph, Benedetto, Chiara, Pfeil, Joop, Schäuble, Barbara, Oene, Joop van, and del Rio, Margarita Sanchez

Subjects
Topiramate, Adult, Male, Migraine without Aura, medicine.medical_specialty, Aura, media_common.quotation_subject, Migraine with Aura, Medizin, Fructose, Severity of Illness Index, Menstruation, Internal medicine, Severity of illness, Medicine, Humans, Prospective Studies, Prospective cohort study, Menstrual cycle, Menstruation Disturbances, media_common, Gynecology, business.industry, General Medicine, Middle Aged, medicine.disease, Contraceptives, Oral, Combined, Clinical research, Treatment Outcome, Migraine, Anticonvulsants, Female, Neurology (clinical), business, medicine.drug
Abstract

Introduction: Preventive treatment with topiramate is effective for overall reduction of migraine frequency, but there are few data regarding its efficacy on perimenstrual migraines. To determine whether topiramate can prevent perimenstrual migraines, we analyzed data from premenopausal women as a subgroup of the Prolonged Migraine Prevention with Topiramate (PROMPT) study. Methods: In total, 198 women from the PROMPT study with menstrually related migraine (MRM) were evaluated. After a one-to-two–month prospective baseline period, patients received open-label topiramate (50–200 mg/day) for six months. Results: During topiramate treatment, mean monthly migraine frequency was reduced from 7.03 at baseline to 4.36 (mean change: −2.66; p Conclusions: Topiramate reduces the frequency, but not severity or duration, of perimenstrual migraines in women with MRM, including migraines with and without aura, and regardless of combined oral contraceptive use.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results